NSE LALPATHLAB · BSE 539524 · Healthcare Facilities · NIFTY 500
Dr. Lal PathLabs Share Price
₹1,950.40
▲ +₹8.35 · 0.43%
Day range · 28 Sep
₹1,908.00Low₹1,962.70High
52-week range
₹1,272.00Low · 23 Mar 2026₹2,035.00High · 16 Sep 2026
Dr. Lal PathLabs Overview
Where the price stands, how it has moved and how it sits against its averages.
Dr. Lal PathLabs shares last traded at ₹1,950.40 on the NSE, up 0.43% on the day. That is 4.2% below the 52-week high of ₹2,035.00 and 53.3% above the 52-week low of ₹1,272.00. The stock trades at 60.60× earnings, above the sector average of 30.19. Its market value is ₹32,838 Cr.
Price returns
1 Day▲ +0.43%
1 Week▲ +2.13%
This month▲ +0.82%
3 Months▲ +18.42%
6 Months▲ +47.16%
This year▲ +31.55%
1 Year▲ +24.51%
Share price growth a year (CAGR): 3 years ▲ +15.6% · 5 years ▲ +0.1% · 10 years ▲ +12.8%
Against the market: 1 Month ▲ +5.71% · 3 Months ▲ +20.59% · 6 Months ▲ +46.68% · This year ▲ +51.86% · 1 Year ▲ +31.50%
Shading grows with the size of the move. We ask our data provider for a newer price every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next check from Fri 16 Oct, 9:15 AM. Its quotes are not real-time — the time at the top shows how current the price is.
Moving averages — price is above 6 of 6
- Today's price₹1,950.40
- 5-day average₹1,933.62 ▲ price 0.9% above
- 10-day average₹1,920.08 ▲ price 1.6% above
- 20-day average₹1,917.03 ▲ price 1.7% above
- 50-day average₹1,885.29 ▲ price 3.5% above
- 100-day average₹1,759.83 ▲ price 10.8% above
- 300-day average₹1,582.34 ▲ price 23.3% above
Each average is the mean closing price over that many trading days; averages above the current price sit higher on the ladder.
Dr. Lal PathLabs Financial Results
Revenue and net profit in ₹ crore, with the full statements underneath.
2,763
505
Year by year
| Fiscal year | Revenue | Growth | Net profit | Net margin | EPS | Dividend |
|---|---|---|---|---|---|---|
| FY 2026 | ₹2,763 Cr | ▲ +12.2% | ₹505 Cr | 18.3% | ₹30.20 | ₹14.00 |
| FY 2025 | ₹2,461 Cr | ▲ +10.5% | ₹487 Cr | 19.8% | ₹29.20 | ₹12.00 |
| FY 2024 | ₹2,227 Cr | ▲ +10.4% | ₹358 Cr | 16.1% | ₹21.49 | ₹12.00 |
| FY 2023 | ₹2,017 Cr | ▼ −3.4% | ₹239 Cr | 11.8% | ₹14.37 | ₹6.00 |
| FY 2022 | ₹2,087 Cr | ▲ +32.0% | ₹345 Cr | 16.5% | ₹20.79 | ₹6.00 |
| FY 2021 | ₹1,581 Cr | ▲ +18.9% | ₹292 Cr | 18.4% | ₹17.62 | ₹10.00 |
| FY 2020 | ₹1,330 Cr | — | ₹226 Cr | 17.0% | ₹13.68 | ₹6.00 |
798
170
Quarter by quarter
| Quarter | Revenue | vs prev. qtr | Net profit | Net margin | EPS |
|---|---|---|---|---|---|
| Q1 FY27 | ₹798 Cr | ▲ +13.5% | ₹170 Cr | 21.2% | ₹10.13 |
| Q4 FY26 | ₹703 Cr | ▲ +6.5% | ₹131 Cr | 18.7% | ₹7.85 |
| Q3 FY26 | ₹660 Cr | ▼ −9.7% | ₹91 Cr | 13.7% | ₹5.42 |
| Q2 FY26 | ₹731 Cr | ▲ +9.1% | ₹151 Cr | 20.6% | ₹9.01 |
| Q1 FY26 | ₹670 Cr | ▲ +11.2% | ₹132 Cr | 19.8% | ₹7.98 |
| Q4 FY25 | ₹603 Cr | ▲ +1.0% | ₹155 Cr | 25.7% | ₹9.28 |
| Q3 FY25 | ₹597 Cr | ▼ −9.6% | ₹97 Cr | 16.2% | ₹5.79 |
| Q2 FY25 | ₹660 Cr | — | ₹129 Cr | 19.6% | ₹7.74 |
Balance sheet — FY26
Owes (liabilities)Shareholders' equity
20%
80%
- Total assets₹3,146 Cr
- Total liabilities₹638 Cr
- Shareholders' equity₹2,508 Cr
- Total debt₹199 Cr
- Cash & investments₹1,387 Cr
- Current ratio3.48×
- Revenue growth, 5 yr11.81% a year
- EPS growth, 5 yr11.37% a year
- Operating margin (TTM)22.00%
- Net margin (TTM)18.90%
Cash flow — FY26
Operating activities
▲ ₹636 Cr
Investing activities
▼ −₹422 Cr
Financing activities
▼ −₹264 Cr
Free cash flow
▲ ₹462 Cr
Net change in cash
▼ −₹50 Cr
Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.
Full financial statements, FY20–FY26
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total revenue | 1,330.36 | 1,581.27 | 2,087.41 | 2,016.88 | 2,226.64 | 2,461.40 | 2,762.91 |
| Cost of revenue | 315.45 | 415.89 | 524.37 | 473.06 | 477.59 | 508.62 | 562.87 |
| Gross profit | 1,014.91 | 1,165.38 | 1,563.04 | 1,543.82 | 1,749.05 | 1,952.77 | 2,200.04 |
| Operating expenses | 1,059.59 | 1,222.01 | 1,632.88 | 1,677.24 | 1,758.49 | 1,902.10 | 2,167.26 |
| Operating income | 270.77 | 359.25 | 454.53 | 339.64 | 468.15 | 559.30 | 595.66 |
| Depreciation | 72.81 | 77.20 | 108.11 | 150.19 | 143.34 | 141.58 | 161.23 |
| Profit before tax | 310.50 | 394.41 | 474.98 | 343.83 | 505.45 | 624.80 | 669.09 |
| Tax | 82.92 | 97.93 | 124.69 | 102.75 | 143.16 | 132.55 | 159.33 |
| Net profit | 225.94 | 291.62 | 344.83 | 238.85 | 357.74 | 487.14 | 504.78 |
| EPS (₹) | 13.68 | 17.62 | 20.79 | 14.37 | 21.49 | 29.20 | 30.20 |
| Dividend per share (₹) | 6.00 | 10.00 | 6.00 | 6.00 | 12.00 | 12.00 | 14.00 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total assets | 1,374.31 | 1,661.33 | 2,346.75 | 2,385.56 | 2,455.96 | 2,716.79 | 3,146.00 |
| Current assets | 892.65 | 1,145.17 | 875.15 | 973.09 | 1,126.70 | 1,363.51 | 1,566.49 |
| Cash & short-term investments | 731.74 | 984.03 | 681.66 | 814.31 | 942.60 | 1,164.07 | 1,386.50 |
| Inventory | 62.32 | 44.62 | 55.13 | 35.53 | 38.76 | 40.19 | 46.73 |
| Property, plant & equipment | 302.10 | 312.01 | 429.82 | 403.97 | 346.98 | 339.28 | 489.32 |
| Total liabilities | 341.50 | 416.27 | 845.14 | 719.26 | 606.68 | 544.07 | 637.86 |
| Current liabilities | 227.31 | 274.28 | 499.99 | 469.75 | 463.58 | 402.35 | 450.62 |
| Total debt | 129.37 | 150.48 | 532.56 | 419.50 | 246.93 | 157.43 | 198.99 |
| Total equity | 1,032.81 | 1,245.06 | 1,501.61 | 1,666.30 | 1,849.28 | 2,172.72 | 2,508.14 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| From operations | 283.89 | 398.15 | 446.69 | 456.03 | 535.33 | 568.89 | 635.61 |
| From investing | −26.11 | −212.02 | −449.25 | −287.31 | −24.27 | −303.16 | −421.86 |
| From financing | −190.45 | −138.56 | 136.45 | −283.18 | −413.86 | −334.03 | −263.57 |
| Capital expenditure | −79.62 | −59.59 | −476.14 | −44.57 | −57.43 | −53.87 | −173.38 |
| Dividends paid | −155.50 | −99.48 | −116.66 | −103.01 | −201.17 | −207.30 | −222.62 |
| Net change in cash | 67.33 | 47.58 | 133.90 | −114.46 | 97.20 | −68.31 | −49.83 |
Dr. Lal PathLabs vs Peers
Side by side with other healthcare facilities companies. The small bars compare each column.
| Company | Price | Change | Market cap | P/E | P/B | ROE (5 yr) | Net margin | Div. yield |
|---|---|---|---|---|---|---|---|---|
| Dr. Lal PathLabs This stock | ₹1,950.40 | ▲ +0.43% | ₹32,838 Cr | 60.60 | 12.99 | 21.32% | 18.90% | 0.82% |
| Apollo Hospitals Enterprise | ₹8,862.00 | ▼ −0.31% | ₹1,27,422 Cr | 64.93 | 13.39 | 18.12% | 7.76% | 0.23% |
| Max Healthcare Institute | ₹1,000.90 | ▼ −1.29% | ₹97,419 Cr | 71.47 | 9.87 | 13.32% | 17.23% | 0.18% |
| Fortis Healthcare | ₹831.60 | ▼ −0.42% | ₹62,782 Cr | 67.89 | 7.27 | 9.36% | 11.66% | 0.10% |
| Aster DM Healthcare | ₹748.00 | ▼ −1.48% | ₹65,283 Cr | 102.55 | 9.26 | 7.13% | 9.20% | 0.49% |
| Narayana Hrudayalaya | ₹1,832.00 | ▼ −1.58% | ₹37,361 Cr | 48.07 | 9.08 | 25.72% | 10.26% | 0.22% |
Peer prices and ratios as last reported by the data provider. Company names link to their own pages.
Dr. Lal PathLabs Key Metrics
Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.
Dr. Lal PathLabsBenchmarkRule-of-thumb bands
Valuation The price against earnings, book value and sales
P/E (TTM)Price ÷ yearly earnings per share
60.60
▲ 101% above the sector average of 30.19
P/E, 12-month rangeLow 42.45 · high 86.33
41%
Today's P/E sits 41% of the way from its low to its high
P/BPrice ÷ book value per share
12.99
P/SMarket cap ÷ last 12 months' revenue
11.36
P/CFPrice ÷ cash flow per share
45.48
PEGP/E ÷ earnings growth rate
2.14
Profitability Of every ₹100 of sales, how much is kept?
Gross marginKept after the cost of goods
80.72%
▲ above its 5-yr average of 77.96%
Operating marginKept after running costs
22.00%
▲ above its 5-yr average of 20.92%
Pre-tax marginKept before tax
24.79%
▲ above its 5-yr average of 22.66%
Net marginKept as profit
18.90%
▲ above its 5-yr average of 16.92%
Returns & efficiency How well does it use its money?
Return on equityProfit on shareholders' money
21.57%
▲ above its 5-yr average of 21.32%
Return on assetsProfit on everything it owns
17.39%
▲ above its 5-yr average of 15.89%
Return on investmentProfit on long-term capital
20.63%
▲ above its 5-yr average of 19.67%
Return on capital employedProfit before interest and tax on equity + debt
26.57%
Growth Is the business getting bigger?
Revenue — last 12 months
+14.3%
▲ growing
Revenue — 3 yr, a year
+11.1%
▲ growing
Revenue — 5 yr, a year
+11.8%
▲ growing
Net profit — 3 yr, a year
+28.3%
▲ growing (off the scale)
Net profit — 5 yr, a year
+11.6%
▲ growing
EPS — last 12 months
+5.2%
▲ growing
EPS — 3 yr, a year
+28.1%
▲ growing (off the scale)
EPS — 5 yr, a year
+11.4%
▲ growing
Dividend — 3 yr, a year
+32.6%
▲ growing (off the scale)
Book value — 5 yr, a year
+14.8%
▲ growing
Financial strength Can it pay its bills and debts?
Debt to equityBorrowings for every ₹1 of shareholders' money
0.08×
Current ratioShort-term assets for every ₹1 due within a year
3.48×
Quick ratioLike the current ratio, without inventory
3.37×
Interest coverOperating profit ÷ interest to pay
27.30×
Payout ratioShare of profit paid as dividend
46.36%
Per share What each share stands for
EPS (TTM)
₹32.40
Book value
₹150.19
Cash flow
₹42.92
Dividend
₹16.00
Revenue
₹172.86
The share price is 12.99× the book value behind each share.
Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.
All 111 metrics from the data provider
Valuation
P/E excluding extraordinary items, most recent fiscal year64.65
Current Dividend Yield - Common Stock Primary Issue, LTM0.82
Price to Book - most recent fiscal year13.00
P/E Basic excluding extraordinary items - TTM50.72
P/E including extraordinary items - TTM60.26
P/E excluding extraordinary items low, trailing 12 months42.45
Price to Tangible Book - most fiscal year18.47
Dividend Yield - 5 Year Average0.85
Price to sales - most recent fiscal year11.82
Dividend Yield - indicated annual dividend divided by closing price0.82
Price to Cash Flow per share - trailing 12 month45.48
Peg Ratio2.14
Price to Free Cash Flow per Share - most recent fiscal year136.24
P/E Normalized, most recent fiscal year61.76
P/E excluding extraordinary items high, trailing 12 months86.33
P/E excluding extraordinary items, most recent fiscal year quarter60.26
Price to sales - trailing 12 month11.29
Net Debt, LFY−11,875.11
Per share
Dividend Per Share - 5 year average10.00
Cash Flow per share - trailing 12 month42.92
Cash Flow per share - most recent fiscal year40.14
EPS including extraordinary items - trailing 12 month32.40
EPS including extraordinary items - most recent fiscal year30.20
EBITD per share - trailing 12 month50.09
Revenue/share - trailing 12 month172.86
EPS excluding extraordinary items - trailing 12 month32.40
EPS Basic excluding extraordinary items - most recent fiscal year30.24
EPS Basic excluding extraordinary items - trailing 12 month32.45
Book value per share - most recent fiscal year150.21
Dividend per share - most recent fiscal year14.00
Revenue/share - most recent fiscal year165.29
EPS Normalized - most recent fiscal year31.61
Book value (tangible) per share - most recent fiscal year105.84
Dividends per share - trailing 12 month16.00
EPS excluding extraordinary items - most recent fiscal year30.20
Cash per share - most recent fiscal year83.04
Margins
Operating margin - trailing 12 month22.00
Gross Margin - 5 year average77.96
Operating margin - 1st historical fiscal year21.56
Operating Margin - 5 year average20.92
Net Profit Margin % - 1st historical fiscal year18.45
Gross Margin - 1st historical fiscal year79.63
Net Profit Margin % - trailing 12 month18.90
Net Profit Margin - 5 year average16.92
Pretax Margin - 5 year average22.66
Pretax margin - 1st historical fiscal year24.22
Pretax margin - trailing 12 month24.79
Free Operating Cash Flow/Revenue, 5 Year Average8.54
Gross Margin - trailing 12 month80.72
Growth
EPS Change %, TTM over TTM5.21
Revenue growth rate, 5 year11.81
EPS growth rate, 5 year11.37
Revenue Change % - most recent quarter 1 year ago19.10
Growth rate% - dividend, 3 year32.64
Growth rate% - EPS, 3 year28.09
Revenue/share (5 yr growth)11.58
Free Operating Cash Flow, 5 Year CAGR0.04
Tangible Book Value, Total Equity, 5 Year CAGR9.94
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR7.74
Capital Spending growth rate, 5 year23.81
Revenue Change %, TTM over TTM14.29
Growth rate% - Revenue, 3 year11.06
Book value per share growth rate, 5 year14.80
EPS Change % - most recent quarter 1 year ago26.95
Net Profit Margin growth rate, 5 year−0.32
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR12.53
Total Debt, 5 Year CAGR5.75
Financial strength
Free Cash Flow - most recent fiscal year2,396.10
LT debt/equity - most recent fiscal year0.06
Quick ratio - most recent fiscal year3.37
Payout ratio - trailing 12 month23.11
Current ratio - most recent fiscal year3.48
Current EV/Free Cash Flow, LFY114.52
Total debt/total equity - most recent fiscal year0.08
Net Interest coverage - trailing 12 month27.30
Payout ratio - most recent fiscal year13.28
Returns & efficiency
Return on average equity - 5 year average21.32
Net Income/employee - trailing 12 month10,49,278.00
Revenue/employee - most recent fiscal year54,24,919.00
Return on investment - most recent fiscal year20.63
Return on average assets - most recent fiscal year17.39
Receivables turnover - most recent fiscal year23.68
Inventory turnover - most recent fiscal year12.95
Revenue/employee - trailing 12 month55,52,845.00
Return on average assets - 5 year average15.89
Net Income/employee - most recent fiscal year10,00,891.00
Asset turnover - most recent fiscal year0.94
Return on average equity - most recent fiscal year21.57
Return on investment - 5 year average19.67
Price & volume
Market Cap32,827.39
52 week Low Date23 Mar 2026
Price - 1 Day % Change−0.46
Relative (S&P500) price percent change - 13 week20.59
Avg trading volume last 10 days0.44
Price - 13 week price percent change15.58
Price - 52 week price percent change19.73
Avg Trading Volume Last 3 months7.71
Price - 5 Day % Change2.92
Price % Change Month To Date0.91
Relative (S&P500) price percent change - 04 week5.71
52 week High Date16 Sep 2026
Price - 26 week price percent change47.30
PDATE25 Sep 2026
Price - YTD price percent change31.68
Relative (S&P500) price percent change - 52 week31.50
NPRICE1,952.30
Relative (S&P500) price percent change - 26 week46.68
52 week Low1,272.60
52 week High2,038.60
Beta0.84
Relative (S&P500) price percent change - Year to Date51.86
Dividends & Corporate Events
Payouts to shareholders, splits and bonus issues, and company meetings — newest first.
₹14.00
- Dividend yield0.82%
- Payout ratio46.36%
- 5-year average dividend₹10.00 a share
- Latest dividend₹5.00 per share · 30 Jul 2026
Corporate calendar
- Upcoming · BoardQuarterly Results
- Dividend₹5.00 per share · 50% · Interim dividend
- MeetingAnnual General Meeting
- BoardQuarterly Results
- Dividend₹4.00 per share · 40% · Final dividend
- BoardAudited Results & Final Dividend
- Dividend₹3.50 per share · 35% · Interim dividend
- BoardQuarterly Results & Interim Dividend
- BonusBonus issue of equity shares in the ratio of 1:1 of Rs. 10/-.
Show 14 older events
- MeetingPostal Ballot
- Dividend₹7.00 per share · 70% · Interim dividend
- BoardQtr Results, Int.Dividend & Bonus issue
- Dividend₹6.00 per share · 60% · Interim dividend
- BoardQuarterly Results, Dividend & Others
- MeetingAnnual General Meeting
- Dividend₹6.00 per share · 60% · Final dividend
- BoardAudited Results & Final Dividend
- MeetingPostal Ballot
- Dividend₹6.00 per share · 60% · Interim dividend
- BoardQuarterly Results, Dividend & Others
- Dividend₹6.00 per share · 60% · Interim dividend
- MeetingAnnual General Meeting
- MeetingAnnual General Meeting
About Dr. Lal PathLabs
Healthcare Facilities
Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services. The Company is engaged primarily in the business of running laboratories for carrying out pathological investigations in various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It offers a range of tests, including Pregnancy Test, Full Body Checkups, Covid 19 Test, Heart Test, Kidney Test, Liver Test, Cholesterol Test, Hepatitis B Test, Kidney Function Test, Sugar Test, Thyroid Test, Typhoid Test, Uric Acid Test, Vitamin B12 Test and vitamin D Test. It has approximately 298 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab in Kolkata, Bangalore and Mumbai), 6,607 patient service centers, and 12,365 pick-up points (PUPs). Its customers include individual patients, hospitals, and corporate customers.
Key people
- Arvind LalExecutive Chairman of the Board
- Shankha BanerjeeChief Executive Officer
- Ved Prakash GoelGroup Chief Financial Officer and Chief Executive Officer - International Business
- Jai Prakash MeenaChief Operating Officer
- Manoj Kumar GargGroup Chief Human Resources Officer
- Munender SopernaGroup Chief Information and Digital Officer
Company facts
- NSE symbolLALPATHLAB
- BSE code539524
- ISININE600L01024
- IndustryHealthcare Facilities
- IndexNIFTY 500
- Market cap₹32,838 Cr
- Revenue (FY26)₹2,763 Cr
- Net profit (FY26)₹505 Cr
In the News
Recent headlines about Dr. Lal PathLabs — they open on Mint in a new tab.
- Dr Lal PathLabs adds genomics heft with SN Genelab deal
SN Genelab’s testing capabilities could gain wider reach through Dr Lal's network over time, potentially boosting growth
28 Sep 2026 · 1 min read · Mint ↗ - Tata Capital Healthcare Fund leads $30 million investment in Tenet Diagnostics
Tata Capital Healthcare Fund and Blue Earth Capital have put $30 million into Tenet Diagnostics, marking one of the first deployments from TCHF's newly closed Fund III.
17 Aug 2026 · 2 min read · Mint ↗
Stock data comes from the exchange feed via our data provider. It is not real-time and can be delayed, so check the price with your broker before you trade. This page is for information and education only. It is not investment advice, research or a recommendation to buy, sell or hold any security. Investments in the securities market are subject to market risks; read all related documents carefully before investing. See all stocks →
Frequently Asked Questions
Dr. Lal PathLabs (NSE: LALPATHLAB) last traded at ₹1,950.40 on the NSE, up 0.43% (₹8.35) on the day, as of 29 Sep 2026. The day's range on 28 Sep was ₹1,908.00 – ₹1,962.70.
Dr. Lal PathLabs's 52-week high is ₹2,035.00 (16 Sep 2026) and its 52-week low is ₹1,272.00 (23 Mar 2026). At ₹1,950.40 the share is 4.2% below its high and 53.3% above its low.
Dr. Lal PathLabs's market capitalisation is ₹32,838 Cr (₹32,838 Cr). It is part of the NIFTY 500 index.
Dr. Lal PathLabs's P/E ratio (trailing 12 months) is 60.60. The sector average is 30.19, so investors pay 101% more for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹32.40.
Dr. Lal PathLabs shares are up 24.51% over the last year, up 31.55% so far this year, up 47.16% over 6 months, up 18.42% over 3 months. Over the last year the stock did 31.50% better than the market.
In FY26 (year to Mar 2026), Dr. Lal PathLabs reported revenue of ₹2,763 Cr (up 12.25% on the year before) and a net profit of ₹505 Cr. Earnings per share were ₹30.20.
Yes. Dr. Lal PathLabs's latest dividend is ₹5.00 per share (50%, interim dividend), with an ex-date of 30 Jul 2026. The dividend yield is 0.82%. It has paid 8 dividends in the records shown on this page.
As of Jun 2026: Promoter 53.19%, FII 17.35%, MF 18.79%, Other 10.67%. Promoter holding fell by 0.02 percentage points from Mar 2026.
Dr. Lal PathLabs's listed peers in Healthcare Facilities include Apollo Hospitals Enterprise, Max Healthcare Institute, Fortis Healthcare, Aster DM Healthcare, Narayana Hrudayalaya. By market capitalisation it ranks #6 of 6 in this group.
No. Dr. Lal PathLabs has debt — its debt-to-equity ratio is 0.08 and total debt was ₹199 Cr in FY26.